Matinas BioPharma Holdings Inc (MTNB)
Matinas BioPharma Holdings Inc. is a clinical-stage biopharmaceutical company listed on the NYSE under the ticker MTNB. The company focuses on developing drug candidates through its lipid nanocrystal platform, which is designed to support delivery of a range of therapeutic payloads, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead program is MAT2203, an oral amphotericin B formulation that has entered Phase 3 testing for certain fungal infections and for prevention of invasive fungal disease in immunosuppressed patients. Matinas BioPharma also develops MAT2501, an oral amikacin formulation, and works with partners including the National Institute of Allergy and Infectious Diseases, BioNTech SE, and Genentech Inc. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-MTNB
|
$0.45
|
66.5% Upside
|
Bargain
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-0.2x
|
0.7x
|
—
|
2.016 M
|
807.028 K
|
37.1%
|
65.3%
|
-54.0
|
—
|
58.8%
|
